Skip to main content
. 2018 Oct 15;2018(10):CD007927. doi: 10.1002/14651858.CD007927.pub4

Comparison 1. EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Overall survival 1   Hazard Ratio (Random, 95% CI) Subtotals only
2 Progression‐free survival 1   Hazard Ratio (Random, 95% CI) Subtotals only